Home › Prostate Cancer › NCT04354064

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Eligible healthy donors will be at least 18 years of age.

Exclusion Criteria:

* Healthy donors younger than 18 years of age

About the study

Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.

Sponsor: Washington University School of Medicine · Participants: 100 · Started: May 29, 2019

Contact the study team

• Melissa Reimers, M.D. · Phone: 314-362-7249

Official record on ClinicalTrials.gov — NCT04354064

Locations in the U.S.

Conditions

• Prostate Cancer
• Head and Neck Cancer
• Esophageal Cancer
• Urogenital Cancer
• Soft Tissue Sarcoma
• Breast Cancer
• Colon Cancer
• Gastrointestinal Cancers
• Lung Cancer
• Skin Cancer
• Melanoma

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.